184 related articles for article (PubMed ID: 19089671)
1. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun W; Tao Y
Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
[TBL] [Abstract][Full Text] [Related]
3. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
7. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
[TBL] [Abstract][Full Text] [Related]
8. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
11. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
Pinter M; Sieghart W; Reisegger M; Wrba F; Peck-Radosavljevic M
Wien Klin Wochenschr; 2011 Jan; 123(1-2):61-4. PubMed ID: 21240686
[TBL] [Abstract][Full Text] [Related]
13. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Hiles JJ; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
15. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
Chung V
Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract][Full Text] [Related]
18. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
[TBL] [Abstract][Full Text] [Related]
19. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
